NCT04764214 is a Phase 2 clinical trial of 3rd generation EGFR-TKI in NSCLC Stage IV, sponsored by Fudan University.

Who is sponsoring NCT04764214?

NCT04764214 is sponsored by Fudan University.

What drugs are being tested in NCT04764214?

Interventions in NCT04764214: 3rd generation EGFR-TKI, Consolidative SRT.

What condition does NCT04764214 study?

NCT04764214 studies NSCLC Stage IV, EGFR Activating Mutation.

Is NCT04764214 still recruiting?

NCT04764214 is currently completed. Last updated 19 August 2024.

Last reviewed 2024-08-19 · How we verify

NCT04764214

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Completed Phase 2 Last updated 19 August 2024

What this trial tests

Phase 2 trial testing 3rd generation EGFR-TKI in NSCLC Stage IV in 61 participants. Completed in 20 July 2023.

Timeline

1 March 2021

Primary endpoint
31 March 2023

20 July 2023

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	61
Start date	1 March 2021
Primary completion	31 March 2023
Estimated completion	20 July 2023
Sites	1 location across China

Drugs / interventions tested

3rd generation EGFR-TKI — full drug profile →
Consolidative SRT

Conditions studied

NSCLC Stage IV — all drugs for NSCLC Stage IV →
EGFR Activating Mutation — all drugs for EGFR Activating Mutation →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with NSCLC Stage IV or EGFR Activating Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an open-label, single-arm phase 2 trial to evaluate the efficacy and safety of stereotactic radiotherapy (SRT) for patients with oligo-residual NSCLC after 3rd generation EGFR-TKIs.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial.
Zhou Y, Peng L, Liang F, Chu L, et al · · 2024 · cited 21× · PMID 39398493 · DOI 10.1016/j.eclinm.2024.102853
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.
Liao YY, Tsai CL, Huang HP. · · 2025 · cited 11× · PMID 39941826 · DOI 10.3390/cancers17030459
Narrative review of stereotactic body radiation therapy combined with tyrosine kinase inhibitors for oligometastatic <i>EGFR</i>-mutated non-small cell lung cancer: present and future developments.
Zhao X, Zhang S, Sun X, Lin Y, et al · · 2024 · cited 7× · PMID 38973945 · DOI 10.21037/tlcr-24-414
Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysis.
Li W, Wu P, Liang Z, Li L, et al · · 2024 · cited 1× · PMID 39506792 · DOI 10.1186/s13014-024-02538-y
Insights on Oligometastatic Non-Small-Cell Lung Cancer.
Valdivia A, Mascaro-Baselga P, Salva-de Torres C, Geng-Cahuayme A, et al · · 2025 · PMID 40805152 · DOI 10.3390/cancers17152451
Concurrent afatinib and stereotactic body radiotherapy in patient with oligometastatic <i>EGFR</i>-mutated non-small cell lung cancer: a case report and literature review.
Sun L, Tao D, Lv Y, Wang C, et al · · 2025 · PMID 40330948 · DOI 10.21037/acr-24-174

Verify or expand the search:

Other recruiting trials for NSCLC Stage IV

Currently open trials in the same condition.

NCT07279402 — TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% · recruiting
NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
NCT06532149 — ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · recruiting
NCT06313541 — Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunothera · Phase 2 · recruiting
NCT06788366 — AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04764214 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 19 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04764214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing